cyrilzakka/clinical-trials huggingface dataset:
Effects of Electric Massage on the Cervical Region in Subjects Diagnosed With Temporomandibular Disorders

To know the short-term effects of electric massage applied on the cervical region combined with local techniques on the temporomandibular joint versus an intervention that applies only local techniques in subjects diagnosed with temporomandibular disorders.

This study aims to know the short-term effects of electric massage applied to the cervical region combined with local techniques on the temporomandibular pain versus an intervention that applies only local techniques in subjects diagnosed with temporomandibular disorders. This is a prospective, controlled, single-blind clinical trial of 46 subjects randomly divided into two groups: Group 1 Manual Therapy=21; Group 2 Interferential massage plus Manual Therapy=25. Group 1 will receive manual therapy consisting of techniques of ischemic compression on masseter muscles and soft-tissue release technique over the temporal región. Group 2, in addition to the intervention in group 1, will receive electric massage with interferential currents at the cervical level.

Pain related measures (Visual Analogue Scale oral, Pressure Pain Threshold (PPT)), vertical mouth opening as primary outcome measures and cervical range of motion as secondary outcomes were assessed. The assessments were made before the intervention, immediately after and after 4 weeks of follow-up.

Eligibility Criteria:
Inclusion Criteria:

* Consent of the subject to participate in the study.
* A primary diagnosis of myofascial pain according to Axis I, category Ia and Ib (i.e. myofascial pain with or without limited opening) of the Research Diagnostic Criteria for TMD (RDC ⁄ TMD) (Schiffman E, Ohrbach R, Truelove E, et al. Diagnostic criteria for tempormandibular disorders (DC(TMD) for clinical and research applications: recommendations of the International RDC/TMD consortium network\* and orofacial pain special interest group. J Oral facial pain headache. 2014;28(1):6-27").
* Bilateral pain involving the masseter and temporal regions; presence of at least one trigger point (TrP) in the masseter muscle.
* Pain symptoms history of at least the 3 months previous to the study.
* Intensity of the pain of at least 30 mm on a 100 mm Visual Analogue Scale (VAS).
* A score of less than 45 points on the Personal Psychological Apprehension Scale (PPAS). It has been validated in the scope of physiotherapy, and represents a simple-to-handle tool in studies where subjects may undergo electrotherapy as a treatment option.

Exclusion Criteria:

* Surgical intervention of the temporomandibular joints (TMJ).
* Suffering some intra-articular damage (arthritis) or some vestibular disorder diagnosed.
* Inflammation of the TMJ.
* Having received physiotherapy treatment in the last two weeks.
* Receive pharmacological treatment for analgesic, anti-inflammatory or that could cause alterations of equilibrium.
Bradycardia Risk Stratification With Loop Recorder After Syncope

Syncope is a common symptom that may be related to a conductive disorder. If no bradycardia is authenticated, it is often necessary to implant an implantable loop recorder.

In somes cases, implantable loop recorder records cardiac conductive disorders. In this study, we want to try to identify a group of patients for whom we could immediately implant a pacemaker without prior implantation of an implantable loop recorder given the high probability of implantation of a pacemaker after interrogation of the implantable loop recorder. It would be interesting for the reduction of interventions for the patients and for the economic aspect of the healthcare system


Eligibility Criteria:
Inclusion Criteria:

* All patients who have benefited from an Implantable Loop recorder in the Nancy's Teaching Hospital

Exclusion Criteria:

* No Exclusion Criteria
Frequency of Hepatobilliary Manifestations in Patients With Inflammatory Bowel Disease

Hepatobilliary manifestations as extraintestinal manifestations of IBD are sometimes underdiagnosed which can impair patient prognosis

Non alcoholic fatty liver is aliver disease most commonly found in patient with IBD most commonly without intestinal activity.

On the other hand primary according cholangitis is the most common specific with IBD commonly with ulcerative colitis. and is commonly overlap with autoimmune hepatitis IBD therapy can also be a cause it can lead to hepatic toxicity and some drugs like ant TNF can cause hepatitis b virus activation.

Eligibility Criteria:
Inclusion Criteria:all patients diagnosed IBD crohns and ulcerative on conventional treatment and biological treatment -

Exclusion Criteria:no

-
A Phase I Study of IGN523 in Subjects With Relapsed or Refractory AML

This study will examine the safety and tolerability of IGN523 administered as an IV infusion. The main purpose of the study is to determine the maximum tolerated dose (MTD), which is the highest dose that does not cause unacceptable side effects of IGN523 in patients with acute myeloid leukemia (AML). The MTD will be determined by observing the dose-limiting toxicities (the side effects that prevent further increases in dose) of IGN523. In addition, the pharmacokinetic profile and anti-leukemia activity of IGN523 will be assessed. A recommended Phase 2 dose (RP2D) of IGN523 will be identified, on the basis of safety, pharmacokinetic (PK), and pharmacodynamic (PD) data.

Primary Objectives:

* Evaluate the safety and tolerability of IGN523 administered weekly
* Determine the MTD and dose limiting toxicity (DLT) of IGN523 when administered weekly during the DLT Evaluation Period
* Identify a recommended Phase 2 dose (RP2D) of IGN523 on the basis of safety, PK, and PD data

Secondary Objectives:

* Assess the incidence of antibody formation to IGN523
* Characterize the PK of IGN523 in subjects with relapsed or refractory AML
* Perform a preliminary assessment of the anti-leukemic activity of IGN523 in subjects with relapsed or refractory AML
* Perform a preliminary assessment of biologic markers that might predict IGN523 anti-leukemic activity

Estimated Enrollment: 50 Study Start Date: February 2014 Estimated Study Completion Date: March 2016 Estimated Primary Completion Date: September 2015 (Final data collection for primary outcome measure)

Eligibility Criteria:
Inclusion Criteria:

* Relapsed or treatment-refractory AML
* Eastern Cooperative Oncology Group status 0-2
* Life expectancy of at least 12 weeks
* Adequate baseline renal and hepatic function
* Measurable disease (eg, peripheral blasts greater than 5%)

Exclusion Criteria:

* Chronic myelogenous leukemia in blast crisis
* Monoclonal therapy within 4 weeks, or chemotherapy or radiotherapy within 2 weeks
* Unresolved acute toxicity from prior anti-cancer therapy
* Prior allogeneic stem cell transplant and active graft-versus-host disease requiring systemic immunosuppressive therapy within 15 days prior to screening
* History of severe allergic or anaphylactic reactions to monoclonal antibody therapy
* Known current leptomeningeal or central nervous system (CNS) involvement of leukemia
Alcohol Abuse or Alcohol Withdrawal: Risk of Latent Scurvy

Scurvy, or latent scurvy, may be underestimated in developed countries, but continue to be described, often as case report. Little is known about the prevalence of vitamin C deficiency in a specific population as withdrawal alcoholics and about his possible consequences, latent scurvy.

In an observational study, the investigators will evaluate prospectively the prevalence of vitamin C deficiency in alcoholic withdrawal patients, its correlation with latent scurvy, mainly tiredness and weakness, and the evolution of the latter at three months after oral vitamin C supplementation.

This study aims to examine:

1. the level of plasma vitamin C for patients that volunteered for alcohol withdrawal. Measurement of vitamin C plasma level will be performed as soon as possible after the agreement as the discussion with the physician could lead to a change in dietary habits. It will be performed by high-pressure liquid chromatography (Cerba Laboratory, F-Cergy Pontoise) according to Lee et al.
2. the correlation between plasma vitamin C level and clinical signs of scurvy, especially signs of latent scurvy like tiredness, leg pain, gums involvement, previously loss of healthy teeth. These signs will be recorded in a structured questionnaire during the first consultation, before knowing the laboratory result patient. All patients who are smoking will perform systematic otorhinolaryngology examination in search of cancer. Other reasons for weakness will be searched by clinical anamneses, body examination, blood probe and abdominal ultrasound examination.
3. the decrease or disappearance of tiredness and/or purpura and/or gums involvement will be studied after vitamin C supplementation in patients whose vitamin C plasma determination is under normal levels and that don't have another explanation for their tiredness. Patients will be evaluated after receiving 1 g oral vitamin C for at least three months.

Ethical considerations The study was approved by the institutional ethics committee of the clinic and was conducted in accordance with the principles of the Declaration of Helsinki. Informed consent was obtained before entry study and each participant agreed to pay for the plasma vitamin C determination.

Dissemination findings Findings for the present study will be reported in manuscripts that will be submitted for publication to a leading medical or nutrition journal in a appropriate field (i.e.alcoholism, nutrition). In addition, findings will be presented as abstracts, posters and presentations at conferences.

Eligibility Criteria:
Inclusion Criteria:

* Patients who volunteered for alcohol detoxification even if they had prior complications of excessive alcohol consumption.
* Each patient provided written consent to the study and agreed to pay himself the determination of the plasma ascorbic level.

Exclusion Criteria:

* Confusion or alcoholic coma.
Comparative Study of Micafungin (FK463) Versus Placebo as Prophylactic Antifungal Therapy in the ICU

The purpose of this study is to determine the efficacy and safety of intravenous micafungin versus placebo as prophylactic therapy for invasive fungal infections in patients in the intensive care unit considered to be at high risk.


Eligibility Criteria:
Inclusion Criteria

* Meets entry criteria for high risk

Exclusion Criteria

* Evidence of active invasive fungal infection
* Received more than one dose of systemic antifungal agent within 72 hours prior to first dose of study drug
* Known to be HIV positive who have CD4 count less than 500 cells/mm3
* Has life-expectancy of less than 72 hours or moribund
Enrollment Barriers, Procedural Denials, and Loss of Medicaid Coverage

The goal of this study is to try new outreach methods to improve access to Medicaid for those who lost Medicaid for procedural reasons. The main questions it aims to answer are:

1. How does a live phone call from a Navigator impact Medicaid enrollment among people who lost Medicaid coverage for procedural reasons?
2. What is the effectiveness of outreach using a live call rather than a pre-recorded call?


Eligibility Criteria:
Inclusion Criteria:

* Eligible for Medicaid
* Lost Medicaid coverage between June 2024 and November 2025

Exclusion Criteria:

* Preferring a language other than English, Spanish, or Hmong
* No working phone number
GLP-2 (Glucagonlike Peptide-2) and Blood Flow

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put.

GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure.

The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).

se the above

Eligibility Criteria:
Inclusion Criteria:

* Age 20-60
* Healthy
* No medication
* Not pregnant

Exclusion Criteria:

* All of the persons not meeting the abowe mentioned criteria
Efficacy of Cevimeline Versus Pilocarpine in the Secretion of Saliva

The main objectives were: 1) To determine the efficacy of both cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and 2) To compare the side-effects between the treatment for xerostomia with cevimeline and with pilocarpine.

Pilocarpine is a cholinergic agonist with predominant muscarinic action.As such, it acts at muscarinic-cholinergic receptors found throughout the body and promotes fluid secretion. Due to this, one of the main side-effects of pilocarpine is an increased amount of sweating. Thus, not only are the salivary glands stimulated, but all of the body's exocrine glands' production is heightened. On the other hand, cevimeline is a drug with a high affinity for specific muscarinic receptors (M3) located on lachrymal and salivary gland epithelium. At least in theory, cevimeline will produce less side effects compared with pilocarpine because of the higher affinity for the muscarinic receptors located in the salivary glands. A limited number of human clinical trials in the efficacy of cevimeline and pilocarpine to increase the production of saliva and the side effects have been performed with no conclusive results.

The main purposes of this study were to determine the efficacy of cevimeline and pilocarpine in the secretion of saliva in patients with xerostomia, and to compare the side-effects between these two medications.

Eligibility Criteria:
Potential candidates with the diagnosis of moderate-severe xerostomia were identified from the Oral Medicine Clinic at the University Of Kentucky College Of Dentistry, or self referrals in response to IRB approved study announcements. Enrollment required no clinical evidence of oral lesions, subjective perception of dry mouth and less than 2 mL of saliva collected in 5 minutes without stimulation. Exclusion criteria included patients with non controlled chronic obstructive pulmonary disease (COPD), depression, asthma, cardiac arrhythmias, glaucoma, and the current use of any medication with interactions with cevimeline and pilocarpine.
Clinical Evaluation of Fenfuro (Fenugreek Seed Extract) in Type-2 Diabetic Subjects: an add-on Study

This study is an open label, two armed trial evaluating the safety and efficacy of Fenfuro capsule twice daily for 90 days in 100 patients with type 2 diabetes that will be conducted in single center in India. The primary outcome measures will be the determination of decrease in plasma glucose levels from baseline to last visit. The secondary outcome will be the determination of safety of Fenfuro capsule in type 2 diabetic subjects.

Diabetes mellitus, involving rise in blood sugar levels, has shown to be a highly prevalent disease. Treatments and treatment regimens include combinations of oral anti-diabetic drugs (OADs), anti-hypertensive medications and anti-dyslipidemic agents, but these have been less than successful in managing their respective disease targets with clinical goals. Now-a-days, the treatment strategies for diabetes mellitus type 2 which are opted by general population include natural supplements. This choice is based upon the involvement of very less side effects along with high effectiveness of the natural supplements as compared to the synthetic medications. One of those natural supplements is fenugreek seeds extract i.e. Fenfuro which has been used as a nutraceutical in the present study for the management of type 2 diabetes mellitus.

Fenugreek has been extensively used as a source of anti-diabetic compounds from long time. Thus, Fenfuro, prepared from fenugreek seeds extract, is supposed to have anti-diabetic properties as well. Previous studies on fenugreek seeds extract have shown effective and safe anti-diabetic and anti-hyperlipidemic properties of it. It has shown to decrease blood glucose levels as well as lipid profile of the diabetic patients.

In this proposed study, Fenugreek seed extract will be used as an add-on to the existing therapy in patients with type-2 diabetes. The efficacy and safety of the extract will be evaluated using standard methodology.

Eligibility Criteria:
Inclusion Criteria:

* Agrees to written as well as audio-visual informed consent.
* Patients of either sex.
* Aged 18-65 years.
* Fasting plasma glucose level \<180 mg/dL.
* HbA1c level more than 7.5%.
* Not receiving any steroids.
* Patient on anti-diabetic therapy.

Exclusion Criteria:

* Uncooperative Subjects.
* Diabetes other than type-2 diabetes mellitus.
* Evidence of renal \& liver disease.
* History of any hemoglobinopathy that may affect determination of HbA1c.
* Lactating and Pregnant or planning to conceive females.
* Physically/ mentally unwell as certified by physician-in-charge.
* Participation in any other clinical trial with in the last 30 days.
* Subjects with allergy to investigational product.
RCT: Titanium vs FCZ vs Zirconia Framework

In recent years, zirconia-based implant-supported bridge designs have begun to be used more and more as an alternative to metal ceramic bridges. Another new material that has been introduced in the clinic is the high translucent monolithic zirconia, which has only been investigated a few follow-up studies with short follow up duration.

The aim being to evaluate the clinical outcome of implant-anchored posterior bridges, made from

1. high-translucent monolithic zirconia,
2. zirconia ceramic with porcelain and
3. metal ceramics. The hypothesis is that high-translucent monolithic zirconia has lower rate of complications since surface porcelain veneering is not required.

A total of 60 research subjects will be included in the study. Patients in need of a permanent implant-supported bridge, located posterior of the canine in the upper or lower jaw will be asked for participation. Each subject will be treated according to standard treatment protocols with implants from Nobel Biocare, the Branemark implant system and then be randomly assigned to obtain one of the following three type of bridges.

20 research subjects will be included in each of the three study arms. The prosthetic treatment will be carried out according to standard clinic protocol.

All research subjects will be evaluated after 1, 3, 5 years. X-rays and photos will be taken at the installation of the bridges and after 1 and 5 years of follow-up or more frequent, depending on individual indication of the patient and the associated standard clinical care protocol.

Personal data, implant survival, marginal bone loss and biological and technical complications related to the implants will be recorded. Survival of the bridge, technical and biological complication related to the bridge will also be recorded


Eligibility Criteria:
Inclusion Criteria:

edentulous behind the canine in the maxilla or mandible

* older than 18 years

Exclusion Criteria:

* younger than 18 years
* active periodontitis
The Effect of Reiki and Acupressure on Pain, Anxiety and Vital Signs

This research aims to determine the effects of reiki and acupressure applied after percutaneous coronary intervention on pain, anxiety and vital signs during femoral catheter extraction.

In this study, 84 patients with percutaneous coronary intervention were assigned to the reiki, acupressure and control groups by block randomization method.In the acupressure group (n=28) the heart meridian 7th point (HT7) large intestine meridian 4th point (LI4) and pericardial meridian 6th point (PC6) will be applied to a total of three points.Depending on the preparation and compression time on each point, the session duration of each patient will be 18 minutes on average.In the reiki group (n=28) the crown chakra (top of the head), the forehead chakra (above the forehead), the throat chakra (above the throat), the heart chakra (the middle of the chest), the solar plexus (under the chest, above the navel), the sacral chakra (below the navel) and the root chakra (above the coccyx) will be applied to the region of the 7 chakra points on.In the reiki group, the reiki application time will take 21 minutes on average.Routine care will be applied to the control group (n=28).Pre-test data of patients in the acupressure, reiki and control groups will be collected 30 minutes before femoral catheter extraction after percutaneous coronary. Posttest data will be collected five minutes after femoral catheter extraction.

Data will be collected using the "Personal Information Form", "Visual Analog Scale", "State Anxiety Inventory" and "Vital Signs Evaluation Form".

Eligibility Criteria:
Inclusion Criteria:

* 18 years and over,
* Percutaneous coronary intervention (PCI) for the first time,
* Previously planned PCI (elective patients),
* No additional procedure to percutaneous coronary intervention,
* Awake and conscious during percutaneous coronary intervention (not taking sedatives)
* A single sandbag is placed on the intervention area,
* Able to lie flat on his back (without respiratory distress),
* Hemodynamically stable (absence of chest pain and arrhythmia),
* No analgesic drug administered at least four hours before,
* No complications such as hematoma or bleeding in the operation area,
* No deformity or lesion in the areas where acupressure will be applied,
* No previous experience of acupressure and reiki application,
* Not diagnosed with anxiety disorder and not receiving medical treatment,
* Literate,
* Have sufficient communication skills and
* Those who signed the Informed Consent Form to participate

Exclusion Criteria:

* Emergency patients whose PCI was not planned beforehand,
* Bleeding, hematoma, etc. at the femoral intervention site during and after the procedure. developing complications,
* Any deformity, wound or lesion in the areas where acupressure will be applied,
* Coronary angiography only,
* Thrombocyte level less than 100,000 mg/dl,
* Those who did not sign the Informed Consent Form to participate in the study
A Study of Tarceva (Erlotinib) in Patients With Advanced Non-Small Cell Lung Cancer Naive to Chemotherapy

This study will evaluate the efficacy and safety of Tarceva in two groups of patients with non-small cell lung cancer who have not been pre-treated with chemotherapy. One group, consisting of patients who have never smoked, will receive Tarceva 150 mg/day, and the other group, consisting of current/former smokers, will receive Tarceva 150 mg/day increasing to a maximum of 300 mg/day. The anticipated time on study treatment is 1-2 years.


Eligibility Criteria:
Inclusion Criteria:

* adult patients, \>=18 years of age;
* histologically documented advanced non-small cell lung cancer (stage IIIB/IV);
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2;
* no previous chemotherapy.

Exclusion Criteria:

* previous therapy which acts on Epidermal Growth Factor Receptor (EGFR) axis;
* clinical evidence of brain metastasis;
* any unstable systemic disease;
* unable to take oral medication;
* any significant ophthalmological abnormality.
The Evaluation of Thiol Redox Status in Conjunctiva of Dry Eye Patients

Dry eye disease is related with oxidative stress at the ocular surface. GSH is one of the key factor of protect from oxidative stress. To evaluate thiol status of ocular surface cells by monitoring GSH concentration, we can evaluate the severity of dry eye.

The conjunctival cells are collected by impression cytology. Those cells are stained with 100 mM of monochlorobimane (MCB, M-1381, Molecular Probes, Eugene, OR) and propidium iodide (PI). Fluorescent intensity, reflecting the amount of icGSH, was inspected under a confocal laser scan microscope. To detect the GSH levels we used a fluorescent MCB probe with excitation and emission wavelengths of 405 nm and 410-480 nm, respectively. The cell-permeating MCB probe is non-fluorescent but forms a fluorescent adduct with GSH in a reaction catalyzed by glutathione-S-transferase.

Eligibility Criteria:
Inclusion Criteria:

* dry eye patients
* control volunteers

Exclusion Criteria:

* Young (less than 20) patients
* The patients who rejected this study